Corrie Pelc

Corrie Pelc is a seasoned journalist with over 23 years of experience. She currently serves as a writer at Medical News Today, where she covers various health topics in an understandable and accessible manner. Prior to this role, she worked as the communications manager for the California Optometric Association and directed content for OptometryWeb and OphthalmologyWeb. She has also contributed to Exceptional Parent, Bay Area Parent, INVISION, Hepatitis Magazine, KentuckyDoc. Follow her on LinkedIn.

84%

The Daily's Verdict

This author has a mixed reputation for journalistic standards. It is advisable to fact-check, scrutinize for bias, and check for conflicts of interest before relying on the author's reporting.

Bias

100%

Examples:

  • Corrie Pelc reports on various health topics with a focus on providing trustworthy and understandable information.

Conflicts of Interest

75%

Examples:

  • Corrie Pelc has worked as a communications manager for the California Optometric Association and director of content for OptometryWeb and OphthalmologyWeb. This suggests some conflict of interest with reporting on topics related to optometry.

Contradictions

98%

Examples:

  • In one article, Corrie Pelc reported that semaglutide changed taste perception in females with obesity but did not mention any contradictions. In another article, she reported on the potential side effects of Ozempic and Wegovy without any contradictions.

Deceptions

75%

Examples:

  • In one article, Pelc made the statement that everyone tastes foods differently but failed to mention that people with obesity have a weakened sense of taste. In another article, she suggested that obese individuals might perceive sweet tastes as less intense when research indicates this is not the case.

Recent Articles

New Study Finds Semaglutide Improves Taste Sensitivity in Women with Obesity: Implications for Weight Loss

New Study Finds Semaglutide Improves Taste Sensitivity in Women with Obesity: Implications for Weight Loss

Broke On: Monday, 03 June 2024 New research suggests semaglutide, an active ingredient in Ozempic and Wegovy, enhances taste sensitivity in women with obesity. By modifying gene expression and renewing taste buds, semaglutide may reduce cravings for unhealthy foods and aid weight loss. However, potential side effects include dysgeusia.
FDA Investigates Possible Side Effects from GLP-1 Drugs: Suicidal Ideation, Hair Loss and Aspiration

FDA Investigates Possible Side Effects from GLP-1 Drugs: Suicidal Ideation, Hair Loss and Aspiration

Broke On: Saturday, 13 January 2024 The FDA is investigating possible side effects from GLP-1 drugs, including suicidal ideation, hair loss and aspiration. These medications have become popular for both weight loss and type 2 diabetes treatment over the last year. A new study found no link between semaglutide, an active ingredient in GLP-1 drugs like Ozempic and Wegovy, and suicidal ideation but people taking these medications had a lower risk of suicidal thoughts compared with older drugs in U.S studies.